X
<

Must-Read Notes on Merck & Co.’s 4Q17 and 2017 Earnings

PART:
1 2 3 4 5 6 7 8 9 10
Part 6
Must-Read Notes on Merck & Co.’s 4Q17 and 2017 Earnings PART 6 OF 10

Merck’s Immunology and Cardiovascular Products in 4Q17

Immunology and cardiovascular products

Merck & Co.’s (MRK) immunology products include Simponi and Remicade. The company’s cardiovascular products include Zetia, Vytorin, Adempas, and Atozet. The chart below shows revenues for key products from immunology and cardiovascular franchise over last few quarters.

Merck’s Immunology and Cardiovascular Products in 4Q17

Interested in MRK? Don't miss the next report.

Receive e-mail alerts for new research on MRK

Success! You are now receiving e-mail alerts for new research. A temporary password for your new Market Realist account has been sent to your e-mail address.

Success! has been added to your Ticker Alerts.

Success! has been added to your Ticker Alerts. Subscriptions can be managed in your user profile.

Immunology franchise

Remicade is a drug marketed by Johnson & Johnson (JNJ) in major countries outside Europe and marketed by Merck & Co. in major European markets. Remicade reported revenues of $186.0 million in 4Q1 for a 31.0% decline compared to $269.0 million in 4Q16. The decline in revenues for Remicade was due to lower sales of the drug following competition from generic products and biosimilars.

Simponi reported revenues of $217.0 million in 4Q17, representing 17.0% growth in revenues compared to $186.0 million in 4Q16.

Cardiovascular franchise

Merck & Co.’s cardiovascular portfolio comprises Zetia, Vytorin, Adempas, and Atozet. Zetia and Vytorin are used for lowering LDL cholesterol levels. The combined revenues for Zetia and Vytorin fell 42.0% to $509.0 million in 4Q17, compared to $873.0 million in 4Q16. 

Zetia reported revenues of $323.0 million in 4Q17, a 44.0% decline compared to $575.0 million in 4Q16. Vytorin reported revenues of $186.0 million in 4Q17, a 38% decline in revenues compared to $299.0 million in 4Q16.

Adempas’s revenues increased to $79.0 million in 4Q17, representing 63.0% growth in revenues compared to $49.0 million in 4Q16. Atozet’s revenues increased to $54.0 million in 4Q17, representing 7.0% growth compared to $50.0 million in 4Q16. The competing cardiovascular drugs include Pfizer’s (PFE) Lipitor and AbbVie’s (ABBV) Niaspan.

X

Please select a profession that best describes you: